BRIEF-Exelixis gets FDA approval for Cabometyx tablets
April 25, 2016 at 14:00 PM EDT
* Exelixis announces FDA approval of Cabometyx(TM) (Cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy
